Glenn Saldanha – Glenmark: Environment challenging, see 20% growth in FY14

Glenn Saldanha – Glenmark: Environment challenging, see 20% growth in FY14 Pharma major Glenmark says the operating environment is challenging given the slowdown in India and longer time taken by the US drug regulator for product approvals. It is expecting a 20 percent revenue growth in FY14. Glenmark Pharmaceuticals expects 20 percent sales growth in the current financial year, amid what it feels is a challenging operating environment. There is a clear slowdown in India and so the pharma major expects only 18-20 percent growth here in FY2014, Glenn Saldanha, CEO & MD told CNBC-TV18. In the US market, there Read More


ˆ Back To Top